YOLFTbeta
30

301569

301569 · SHE · Healthcare / Drug Manufacturers - General

17.99CNY-1.61 (-8.21%)

Price History

Full chart

Market Stats

Previous Close19.60
Open19.00
Day Range17.77 – 19.40
52-Week Range16.75 – 42.15
Volume32.81M
Market Cap17.18B
P/E (TTM)47.00
Forward P/E0.00
EPS0.41
Dividend Yield0.00%
50-Day Avg20.78
200-Day Avg20.78

About

NOVAST Laboratories, Limited develops, manufactures, and sells prescription drug formulations. The company produces controlled-release formulations, including extended-release and sustained-release tablets and capsules, as well as low-dose drug formulations. Its products include Metoprolol Succinate Extended-Release Tablets, Nifedipine Extended-Release Tablets, Diltiazem Hydrochloride Extended-Release Capsules, Metformin Hydrochloride Sustained-Release Tablets, Levonorgestrel Tablets, Memantine Hydrochloride Extended-Release Capsules, Quetiapine Fumarate Sustained-Release Tablets, and Tolterodine tablets for urinary frequency and urgency. The company also develops a digestive-system extended-release tablet designated DG-062. Additionally, the company provides formulation contract research organization (CRO) services, including prescription process development and regulatory filing and clinical support services for pharmaceutical companies and research institutions, as well as outsourced CRO and contract manufacturing organization (CMO) services for innovative drugs. NOVAST Laboratories, Limited was incorporated in 2005 and is based in Nantong, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Guohua Zhang
  • HeadquartersNo. 1, Guangxing Road, Nantong, China, 226010, China
  • Websitehttps://www.novast.cn

Leadership

  • Dr. Guohua ZhangFounder, GM & Chairman · b. 1949
  • Mr. Shuqiang ZhangDeputy GM, Secretary, CFO & Director · b. 1978
  • Mr. Rajuprasad PinnamarajuDeputy GM & Director · b. 1966
  • Mr. Chen YishengSenior Vice President of Product Development · b. 1955
  • Mr. Chengsong HuDirector of Analytical Research & Development Department and Director · b. 1981
  • Mr. Jian GongEmployee Representative Director & Director of Product R&D · b. 1984

Financials

Income Statement

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Revenue550.07M700.43M866.22M895.47M
Growth (%)-+27.33%+23.67%+3.38%
Cost of Revenue270.38M348.89M394.25M396.44M
Gross Profit279.69M351.54M471.97M499.03M
Gross Margin50.85%50.19%54.49%55.73%
Operating Expense230.96M230.85M214.47M231.35M
Operating Income48.73M120.69M257.51M267.68M
Operating Margin8.86%17.23%29.73%29.89%
EBITDA81.41M155.19M292.14M303.55M
EBITDA Margin14.80%22.16%33.73%33.90%
Net Income113.00M115.79M260.15M227.82M
Net Income Margin20.54%16.53%30.03%25.44%
R&D102.89M88.74M101.73M100.97M
R&D as % of Total Revenue18.70%12.67%11.74%11.28%

Balance Sheet

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Assets1.53B1.75B2.05B2.29B
Total Liabilities200.91M225.90M261.35M283.86M
Total Equity1.33B1.53B1.79B2.01B
Cash475.57M638.07M863.13M1.10B

Cash Flow

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow209.21M200.91M267.02M322.58M
Capital Expenditure69.79M126.96M105.86M75.30M
Free Cash Flow139.42M73.96M161.16M247.28M
Dividends Paid---68.00M
FCF to OCF66.64%36.81%60.36%76.66%
Dividend Paid to FCF---27.50%

Key Statistics & Ratios

Market Cap17.18B
Enterprise Value15.77B
Trailing P/E47.00
Forward P/E0.00
Price / Sales17.01
Price / Book7.53
EPS0.41
Book Value3.01
Revenue (TTM)1.01B
Gross Profit (TTM)588.55M
EBITDA393.08M
Profit Margin30.82%
Operating Margin36.94%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding891.60M
Shares Float34.82M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%